These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11554551)

  • 1. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.
    Palmer GC
    Curr Drug Targets; 2001 Sep; 2(3):241-71. PubMed ID: 11554551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low affinity use-dependent NMDA receptor antagonists show promise for clinical development.
    Palmer GC; Widzowski D
    Amino Acids; 2000; 19(1):151-5. PubMed ID: 11026483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions.
    Jansen M; Dannhardt G
    Eur J Med Chem; 2003; 38(7-8):661-70. PubMed ID: 12932897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
    Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
    Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
    Kornhuber J; Weller M
    Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The low-affinity, use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke.
    Palmer GC; Cregan EF; Bialobok P; Sydserff SG; Hudzik TJ; McCarthy DJ
    Ann N Y Acad Sci; 1999; 890():406-20. PubMed ID: 10668446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA/NR2B selective antagonists in the treatment of ischemic brain injury.
    Wang CX; Shuaib A
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):143-51. PubMed ID: 15857299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NR2B selective NMDA receptor antagonists.
    Nikam SS; Meltzer LT
    Curr Pharm Des; 2002; 8(10):845-55. PubMed ID: 11945135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation?
    Smith PF
    Curr Opin Investig Drugs; 2003 Jul; 4(7):826-32. PubMed ID: 14619404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competitive Gly/NMDA receptor antagonists.
    Catarzi D; Colotta V; Varano F
    Curr Top Med Chem; 2006; 6(8):809-21. PubMed ID: 16719819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.
    Parsons CG; Danysz W; Quack G
    Neuropharmacology; 1999 Jun; 38(6):735-67. PubMed ID: 10465680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice.
    Geter-Douglass B; Witkin JM
    Psychopharmacology (Berl); 1999 Oct; 146(3):280-9. PubMed ID: 10541728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remacemide: current status and clinical applications.
    Schachter SC; Tarsy D
    Expert Opin Investig Drugs; 2000 Apr; 9(4):871-83. PubMed ID: 11060716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy.
    Löscher W; Lehmann H; Behl B; Seemann D; Teschendorf HJ; Hofmann HP; Lubisch W; Höger T; Lemaire HG; Gross G
    Eur J Neurosci; 1999 Jan; 11(1):250-62. PubMed ID: 9987029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials.
    Sang CN
    J Pain Symptom Manage; 2000 Jan; 19(1 Suppl):S21-5. PubMed ID: 10687335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New therapeutic possibilities with low-affinity NMDA receptor antagonists].
    Kornhuber J; Weller M
    Nervenarzt; 1996 Jan; 67(1):77-82. PubMed ID: 8676993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologically activated therapeutics for neuroprotection.
    Lipton SA
    Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.